# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and maintains $15 p...
Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and lowers the pric...
Anika Therapeutics (NASDAQ:ANIK) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(...
Hyalofast consistently demonstrated improvements over microfracture, but missed on statistical significance of the pre-specifie...
Barrington Research analyst Michael Petusky maintains Anika Therapeutics (NASDAQ:ANIK) with a Outperform and lowers the pric...